Prevalence and progression of chronic kidney disease after a liver transplant: a prospective, real-life, observational, two-year multicenter study by Herrero, J.I. et al.
Herrero JI, Cuervas-Mons V, Gómez-Bravo MA, Fabregat J, Otero A, Bilbao 
I, Salcedo MM, González-Diéguez ML, Fernández JR, Serrano MT, Jiménez 
M, Rodrigo JM, Narváez I, Sánchez G. Prevalence and progression of chronic 
kidney disease after a liver transplant: a prospective, real-life, observational, 
two-year multicenter study. Rev Esp Enferm Dig 2018;110(9):538-543.
DOI: 10.17235/reed.2018.5431/2017
Prevalence and progression of chronic kidney disease after liver transplant:  
a prospective, real-life, observational, two-year multicenter study
ORIGINAL PAPERS
José Ignacio Herrero1, Valentín Cuervas-Mons2, Miguel Ángel Gómez-Bravo3, Joan Fabregat4, Alejandra Otero8, 
Itxarone Bilbao5, María Magdalena Salcedo7, María Luisa González-Diéguez8, José Ramón Fernández9,  
María Trinidad Serrano10, Miguel Jiménez10, Juan Miguel Rodrigo11, Isidoro Narváez12 and Gloria Sánchez13
1Digestive and Liver Disease Biomedical Research Network (CIBERehd). Navarra Health Research Institute (IdiSNA). Clínica Universidad de 
Navarra. Pamplona, Spain. 2Medicine Department. Madrid Autonomous University. Puerta del Hierro Research Institute. Hospital Universitario 
Puerta de Hierro. Majadahonda, Madrid. Spain. 3Hospital Virgen del Rocío. Sevilla, Spain. 4Hospital Universitario de Bellvitge. Barcelona, Spain. 
5Hospital Universitario A Coruña. A Coruña, Spain. 6Hepatobiliary and Digestive Transplant Surgery. Hospital Universitario Vall d´Hebron. Barcelona, 
Spain. 7Digestive and Liver Disease Biomedical Research Network (CIBERehd). Hospital Universitario Gregorio Marañón. Madrid, Spain. 8Hospital 
Universitario Central de Asturias. Oviedo, Spain. 9Hospital Cruces. Bilbao, Spain. 10Hospital Clínico Universitario Lozano Blesa. Zaragoza, Spain. 
11Hospital Regional Universitario Carlos Haya. Málaga, Spain. 12Hospital Infanta Cristina. Badajoz, Spain. 13Hospital Universitario Río Hortega. 
Valladolid, Spain
Received: 22/12/2017 · Accepted: 15/04/2018
Correspondence: José Ignacio Herrero. Liver Unit. Clínica Universidad de Navarra. Av. de Pío XII, 36. 31008 
Pamplona, Spain. e-mail: iherrero@unav.es
ABSTRACT
Introduction: chronic kidney disease is a frequent com-
plication after liver transplantation. The use of calcineurin 
inhibitors is one of the causes of this complication. Cur-
rent immunsuppression regimens that reduce the use of 
calcineurin inhibitors may be associated with an improved 
preservation of renal function.
Objective: the study aimed to assess the evolution of renal 
function after liver transplantation in the current routine 
clinical practice.
Methods: an observational, prospective, multicenter 
study in adult liver transplant recipients was performed. 
Two hundred and thirty patients with a good renal func-
tion before transplantation were assessed six months 
post-transplantation (baseline) and every six months until 
month 30.
Results: at baseline, 32% of the patients had a reduction in 
the glomerular filtration rate below 60 ml/min/1.73 m2. The 
mean glomerular filtration rate increased from 72.3 to 75.6 
ml/min/1.73 m2 at baseline and month 30 respectively (p < 
0.01). The mean serum creatinine levels (mg/dl) decreased 
from 1.13 to 1.09 (p < 0.01). The percentage of patients with 
stage 3 chronic kidney disease decreased from 31.7% to 
26.4%, whereas the percentage of patients with stage 4 
remained unchanged (0.4% at baseline and 0.5% at month 
30). No patients progressed to end-stage kidney disease 
that required dialysis or renal transplantation.
Conclusion: in the routine clinical practice, a moderate dete-
rioration of renal function is frequent after liver transplan-
tation. However, advanced chronic kidney disease is infre-
quent in patients with a good pre-transplant renal function.
Key words: Liver transplantation. Nephrotoxicity. Renal 
function. Immunosuppression.
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Chronic kidney disease (CKD) is a worldwide public health 
problem in the general population and also in transplant 
recipients. The National Kidney Foundation Kidney Disease 
Outcomes Quality Initiative (NKF-K/DOQI) and the KDIGO 
CKD guidelines define CKD as an estimated glomerular 
filtration rate (eGFR) of 59 ml per minute per 1.73 m2 of 
body-surface area or less (< 60 ml/min/1.73 m2), or evidence 
of kidney damage such as albuminuria or abnormal find-
ings on renal imaging for three months or more (1,2). CKD 
has a negative impact on the quality of life and is associat-
ed with an increased risk of hospitalization and mortality, 
mainly due to cardiovascular mortality (3).
After solid organ transplantation, a significant decrease in 
renal function occurs in the majority of patients. Depending 
on the degree of kidney injury, a large number of patients 
develop CKD and some develop end-stage renal disease 
that requires renal replacement therapy (4-7). The Scien-
tific Registry of Transplant Recipients at the University of 
Michigan Medical School reported a study, which included 
69,321 patients with a median follow-up of 36 months. The 
incidence of patients with an eGFR < 30 ml/min/1.73 m2 
was 8% at 12 months, 13.9% at 36 months and 18.1% at 60 
months (5). Of the 11,426 patients with CKD, 28.9% required 
chronic dialysis or a secondary renal transplantation. O’Ri-
ordan et al. reported that 70% of liver transplant recipients 
had an impaired renal function (eGFR < 60 ml/min/1.73 m2) 
five years after liver transplantation (LT) (8). 
Calcineurin-inhibitor (CNI) therapy has been identified as 
a major risk factor of CKD in transplant recipients (5,8,9). 
Several studies have shown that it is possible to reduce the 
incidence of acute kidney injury (AKI) and CKD by reducing 
the exposure to CNIs. This is achieved via the combination 
with non-nephrotoxic immunosuppressive drugs (10-13), 
without increasing the risk of graft rejection. Besides, many 
centers have successfully reduced the exposure to neph-
rotoxic immunosuppressive drugs in patients with kidney 
dysfunction. A switch from CNI to an mTOR inhibitor or 
mycophenolate mofetil (MMF) leads to an improvement of 
renal function in a variety of patients (14,15).
We hypothesized that the incidence of CKD in the current 
clinical practice is lower than previously reported, as clini-
cians are more concerned about CNI induced nephrotox-
icity. Therefore, less nephrotoxic immunosuppressive reg-
imens are used. In the present study we aimed to assess 
the incidence and the evolution over time of CKD in the 
routine clinical practice in a recent series of Spanish adult 
liver transplant recipients. 
MATERIAL AND METHODS
Study subjects and design 
This was an observational, prospective, multicenter study 
conducted in adult patients (> 18 years) that received a first LT 
from a brain dead donor. Patients that underwent a transplant 
from 2009 and 2010, with a GFR ≥ 60 ml/min/1.73 m2 and no 
evidence of kidney damage at the time of the transplant were 
included in the study. Post-transplant immunosuppression 
was modified according to the protocol of each hospital.
The study was performed according to the International 
Guidelines for the Ethical Review of Epidemiological Stud-
ies (Council for the International Organizations of Medical 
Sciences [CIOMS], Geneva, 2008) and the Declaration of 
Helsinki (Seoul, October 2008). The study was reviewed 
and approved by the Clinical Research Ethics Committee 
of all participating hospitals. All patients gave their written 
informed consent prior to inclusion in the study. 
CKD definition and classification
CKD was defined according to the NKF-K/DOQI and the KDI-
GO CKD guidelines (1,2). The classification of CKD stages 
was as follows: 
•  Stage 1: normal or increased GFR (> 90 ml/min/ 
1.73 m2).
•  Stage 2: mild reduction in GFR (60-89 ml/min/1.73 m2).
•  Stage 3: moderate reduction in GFR (30-59 ml/min/ 
1.73 m2).
•  Stage 4: severe reduction in GFR (15-29 ml/min/ 
1.73 m2).
•  Stage 5: kidney failure (GFR < 15 ml/min/1.73 m2 or 
dialysis). 
GFR was estimated using the abbreviated Modification of 
Diet in Renal Disease (MDRD) equation (16). The progres-
sion of CKD was defined as a change from stages 1, 2 or 3 
to stage 4 and from any prior stage to stage 5.
Modifications of the CNI dose and levels and the use of 
alternate immunosuppressive regimens in patients with 
kidney dysfunction were defined according to the center 
protocol. Any therapy that slows the rate of progression in 
patients with CKD, independent of any modification of the 
immunosuppressive regimen, was administered according 
to the center protocol.
Data collection
The study was conducted according to the usual clinical 
practice management. Demographic and general data of 
recipients and donors were recorded. This included the 
underlying liver disease, the presence of other comorbidi-
ty, date of LT, use of medication and laboratory data at the 
time of transplantation.
Patients were assessed at six months post-LT (baseline) 
and at six-month intervals for two years; the final visit was 
performed 30 months after the LT. The following laboratory 
data were documented: glycemia and glycated hemoglo-
bin, lipid profile, renal function (serum creatinine [sCr] and 
eGFR), hematology and biochemical data and the dose and 
level of immunosuppressive drugs. The following variables 
were also collected every six months up to month 30 post-
LT: weight, body mass index, blood pressure, concomitant 
treatment (antihypertensive, antidiabetic and hypolipidemic 
drugs), graft rejection episodes and infection episodes.
Statistical analysis
The sample size calculation was based on the published 
proportion of stage 4 CKD three years after LT (13.9%) (5), 
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the capacity to detect a difference of at least 7% in this 
proportion, an alpha error of 0.05, a beta error of 0.20 and 
a 3% estimate of missing patients. The sample size should 
be 219 patients according to these assumptions. Descriptive 
statistics were generated for the assessed variables, includ-
ing the total number of valid values. Continuous variables 
were described by measures of central tendency and dis-
persion and absolute and relative frequencies were used to 
describe categorical variables. The 95% confidence interval 
for the main variable was calculated. A comparison of two 
continuous variables was performed using the Mann-Whit-
ney test (for non-pair-wise data) or Wilcoxon test (for pair-
wise data) for parametric variables. The Chi-squared test (or 
the Fisher exact test, when required) was used to compare 
proportions and frequency distributions. The SPSS Version 
13.0 software was used and all analyses were bilateral with 
a significance level 0.05.
RESULTS
Two hundred and thirty LT recipients (74.3% men) with 
mean age 55.7 ± 9.0 years were enrolled in the study. 
The sociodemographic and clinical characteristics of the 
patients are shown in table 1. Mean time from LT to study 
inclusion was 6.4 months and the most frequent indications 
for transplantation were cirrhosis (56.1%) and liver cancer 
(35.2%). Four patients required transient hemodialysis with-
in the first month after transplantation. 
Evolution of kidney function
Kidney function rapidly worsened within the first months 
after LT and stages 3 and 4 CKD were reported in 31.7 and 
0.4% of the patients at six months post-LT (all patients 
had a GFR ≥ 60 ml/min/1.73 m2 before LT), respectively. 
However, kidney function improved from that time point 
and the mean eGFR increased from 72.3 ml/min/1.73 m2 
at month 6 post-LT to 76.5 ml/min/1.73 m2 at month 12 
and 75.6 ml/min/1.73 m2 at month 30 (p < 0.01) (Fig. 1A). 
The mean levels of sCr significantly decreased from 1.13 
mg/dl at month 6 to 1.07 mg/dl at month 12 and 1.09 mg/
dl at month 30 (p < 0.05) (Fig. 1B). One hundred and four 
(45.2%) patients had sCr values ≥ 1.3 mg/dl at least once 
during the study. However, the proportion of patients 
with sCr ≥ 1.3 mg/dl did not change significantly during 
visits.
CKD was not progressive during the study period. As 
shown in figure 2, the percentage of patients with GFR ≥ 
60 ml/min/1.73 m2 increased from 67.8% at month 6 post-
LT to 68.8%, 73.4%, 70.7% and 73.1% at months 12, 18, 24 
and 30 post-LT, respectively. The percentage of patients 
with stage 3 CKD decreased from 31.7% at month 6 to 
26.4% at month 30. The percentage of patients with stage 
4 CKD remained unchanged during the study; 0.4% at 
month 6 versus 0.5% at the end of the study, which was 
non-significant. None of the patients progressed to stage 
5 end-stage kidney disease that required chronic dialysis 
treatment or a renal transplantation. Renal function was 
stable in patients that received tacrolimus or cyclospo-
rine as a monotherapy and trended to improve in patients 
who received other immunosuppressive therapies (Sup-
plementary Fig. 1).
Evolution of immunosuppression
Initial postoperative immunosuppression consisted of a 
CNI based regimen in all patients; 99.6% of the patients 
remained on CNI at six months post-LT, 67.4% were on an 
anti-proliferative agent, 36.1% were on corticosteroids 
and 10.6% were on mTOR inhibitors. Figure 3 shows the 
evolution of the immunosuppression therapy used during 
the study. The proportion of patients on CNI monotherapy 
Table 1. Sociodemographic and baseline clinical 
characteristics of patients (n = 230)
Age (years) 55.7 ± 9.0
Sex: male/female 171 (74.3%)/59 (25.7%)
BMI† (kg/m2) 26.2 ± 4.3
Abdominal perimeter (cm) 96.6 ± 13.4
SBP (mmHg) 133.5 ± 19.0
DBP (mmHg) 78.4 ± 11.9









Hepatocellular carcinoma 81 (35.2%)
Acute liver failure 8 (3.5%)
Other indications* 8 (3.5%)
Serology‡, n (%)
 CMV + 197 (86.4%)
 EBV + 197 (86.4%)
 HIV + 3 (1.3%)
 HCV + 81 (35.5%)
Immunosuppressive treatment six months after LT (baseline, n [%])
 Tacrolimus 148 (64.3%)
 Mycophenolate 116 (50.4%)
 Steroids 43 (18.7%)
 Cyclosporine A 42 (18.3%)
 Everolimus 20 (8.7%)
 Sirolimus 3 (1.3%)
 Azathioprine 1 (0.4%)
Post-transplant dialysis 4 (1.8%)
Maximum sCr in the first post-transplant 
month (mg/dl)
1.8 ± 0.8 
Time from transplant to study inclusion 
(months)
6.4 ± 1.1
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; 
CMV: cytomegalovirus; EBV: Epstein-Barr virus; HCV: hepatitis C virus; HIV: human 
immunodeficiency virus; ADA: American Diabetes Association; sCr: serum creatinine. Data 
expressed as mean ± SD for continuous and as n (%) for categorical variables. *Other 
indications: familial amyloidotic polineuropathy (three patients), liver metastases of a 
neuroendocrine malignancy (two patients), polycystic liver disease (two patients) and Carolí’s 
disease (one patient). †n = 216; ‡n = 228; §n = 228; ǁn = 227. 
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and there was a gradual decrease of tacrolimus levels over 
time (Fig. 4).
Graft rejection and graft and patient survival
Eighteen (7.8%) patients had episodes of acute graft rejec-
tion during follow-up and all were resolved with an inten-
sification of immunosuppression. Sixteen (6.9%) patients 
died and another required a re-transplant during follow-up. 
DISCUSSION 
In our case series, a rapid decrease in renal function 
occurred in a significant proportion of patients within the 
first months after LT, most probably due to CNI nephrotox-
icity. All the patients in this series had a pre-transplant GFR 
≥ 60 ml/min/1.73 m2 and approximately one third evolved to 
stage 3 CKD as early as six months after LT. Previous stud-
Fig. 1. Evolution of the (A) mean glomerular filtration rate 
(± SD) and (B) mean serum creatinine (± SD) during the 
study period (6-30 months after transplantation) in 205 
patients with values at all the time-points of the study 
(GFR: glomerular filtration rate; LT: liver transplantation; 
SD: standard deviation). 
Fig. 2. Patients with a glomerular filtration rate lower than 
60 ml/min/1.73 m2, between 60 and 90 ml/min/1.73 m2 and 
≥ 90 ml/min/1.73 m2 in 205 patients with values at all the 
time-points of the study (GFR: glomerular filtration rate; LT: 
liver transplantation).
increased during the study. An increase in the proportion 
of patients free of CNI was also found. Interestingly, 20% 
of patients remained on steroids up to 30 months after LT 
A
B Supplementary Fig. 1. Evolution of the glomerular filtration 
rate (ml/min) in patients who received calcineurin inhibitor 
monotherapy (n = 59) or other immunosuppressive 
protocols (n = 142) at the end of follow-up. The 
comparisons between both groups were non-significant at 
all time-points. 
CNI monotherapy Other protocols
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ies have shown that having a low GFR in the first months 
post-transplant (one, three and six months post-transplant) 
is an independent predictor of CKD (17-19). Thus, many cen-
ters aim for lower target levels of CNI in patients with kid-
ney dysfunction (20). 
The proportion of patients with stage 4 CKD (eGFR < 30 
ml/min/1.73 m2) in this study remained at 0.4-0.5% up to 
30 months post-LT. This rate is similar to the estimated 
prevalence of stage 4 CKD in the general population (0.4% 
[21]) and lower than other previously reported rates in liver 
transplant recipients (5). For example, the cumulative inci-
dence of stage 4 CKD were 8% at 12 months, 13.9% at 36 
months and 18.1% at 60 months in the study by Ojo et al. 
(5). The greater percentage of patients with advanced CKD 
in this study might be explained by the significant propor-
tion of patients (26.8%) with a pre-transplant GFR < 60 ml/
min/1.73 m2, which is a known risk factor for subsequent 
CKD (19). Furthermore, the higher levels of CNI frequently 
used at the time of the study. 
In our series, CKD was not progressive during the study 
and seemed to recover over time after LT. In this regard, 
the percentage of patients with stages 1 and 2 increased 
over the time and the percentage of patients with stage 
3 decreased. As mentioned previously, the percentage of 
patients with stage 4 remained unchanged and no patients 
progressed to stage 5. The low risk of developing progres-
sive CKD after LT is probably related to the introduction in 
recent years of new non-nephrotoxic drugs in the immu-
nosuppressive regimens, such as MMF or mTOR inhibitors. 
This has allowed reduced doses of cyclosporine A and tac-
rolimus and led to a reduction of nephrotoxic and cardio-
vascular-related adverse events (19,22-29). Varo et al. (18) 
reported that transplanted patients from 1999 onwards had 
a lower risk of developing CKD than those transplanted pri-
or to 1999, although this effect was attributed to a longer 
evolution time and consequently, an increased exposure 
to immunosuppressive treatment and their toxic effects 
in those patients transplanted before 1999. However, the 
putative effect of the more recent immunosuppressive reg-
imens cannot be ruled out. In fact, non-nephrotoxic drugs 
were introduced in some cases after a clinical diagnosis of 
CKD in that study. The patients transplanted in more recent 
years have most likely benefited from this treatment. In our 
study, more than half of the patients received mycopheno-
lic acid and 10-15% mTOR inhibitors. Both types of drugs 
may have reduced CNIs doses and levels and consequent-
ly, have reduced secondary toxic effects in liver transplant 
patients. In this regard, the GFR and sCr levels improved 
significantly in our study versus the baseline level. This 
improvement seemed to be more evident in patients who 
received non-nephrotoxic drugs. As patients that received 
CNI monotherapy at the end of follow-up maintained a sta-
ble renal function throughout the study, whereas the mean 
eGFR increased in patients that received other immunosup-
pressive therapies. The difference between both groups did 
not reach statistical significance, although this observation 
reinforces the potential benefit of the use of other drugs to 
reduce the nephrotoxicity of CNI. In any case, the design 
of the present study did not allow us to demonstrate that 
the evolution of renal function is a consequence of reduced 
CNI doses.
The limitations of the present study are those that are typi-
cal of observational studies. These include the non-random 
assignment and confounding, a relatively short follow-up 
of 2.5 years, a lack of data for some potential confounders 
and mainly Caucasian participants. Furthermore, the low 
number of patients with stage 4 CKD did not allow an anal-
ysis of risk factors. However, this study has some attractive 
features including the relatively large sample size of the 
cohort, the prospective design and the fact that the patients 
are representative of the routine clinical practice in Spain. 
The results of this study should not be generalized to all 
populations of LT recipients, as the cases included in the 
present study had a normal pre-transplant renal function.
In summary, up to one third of the patients had a moder-
ate reduction in GFR (30-59 ml/min/1.73 m2) during the first 
months after LT. However, kidney function tended to stabi-
lize or improve during the year. Furthermore, CKD was a 
progressive disease to a severe reduction in GFR or kidney 
failure over time in only a few patients. Our results suggest 
that in the current clinical practice, de novo post-transplant 
CKD may be a non-progressive disease.
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